Literature DB >> 230897

Treatment of small cell bronchogenic carcinoma with VM-26.

R L Woods, R M Fox, M H Tattersall.   

Abstract

VM-26 is active in small cell bronchogenic carcinoma even in patients resistant to previous chemotherapy. The overall response rate was 28%, with a response rate of 29% in patients resistant to previous chemotherapy. This response rate is similar to that obtained with other single agents including Adriamycin, vincristine, cyclophosphamide, and procarbazine. The mild subjective and objective toxic effects of the drug make it a potentially useful agent in the treatment of this tumor.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 230897

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  5 in total

Review 1.  VM26: phase I and II studies.

Authors:  F R Macbeth
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

2.  VM-26 in colorectal carcinoma: a Southwest Oncology Group study.

Authors:  N Oishi; T R Fleming; L Laufman; J S Ungerleider; R B Natale; A B Einstein; D D Von Hoff; J S Macdonald
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

Review 3.  The podophyllotoxin derivatives VP16-213 and VM26.

Authors:  B F Issell
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 4.  Current development of podophyllotoxins.

Authors:  R Canetta; P Hilgard; S Florentine; P Bedogni; L Lenaz
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 5.  Teniposide: overview of its therapeutic potential in adult cancers.

Authors:  F M Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.